What meningococcal conjugate vaccine (MenACWY) is recommended for a 1‑year‑old infant and what is the appropriate dosing schedule, including any considerations for MenB vaccination?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: March 7, 2026 • View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Meningococcal Vaccination for a 1-Year-Old Infant

For a healthy 1-year-old infant, meningococcal vaccination is NOT routinely recommended unless the child has specific risk factors that increase susceptibility to invasive meningococcal disease. 1

Routine Vaccination Status

Meningococcal vaccines are not part of the standard immunization schedule for healthy infants at 12 months of age. The routine recommendation begins at 11-12 years of age for MenACWY vaccination 1, 2.

When Vaccination IS Indicated at Age 1 Year

MenACWY vaccination is recommended for 1-year-old infants who have any of the following high-risk conditions 1:

  • Persistent complement component deficiencies (C3, C5-C9, properdin, factor D, factor H)
  • Functional or anatomic asplenia (including sickle cell disease)
  • HIV infection
  • Travel to or residence in areas with hyperendemic or epidemic meningococcal disease (e.g., sub-Saharan Africa "meningitis belt")
  • Exposure during a community meningococcal outbreak

Vaccine Selection and Dosing for High-Risk 1-Year-Olds

If Starting Vaccination at 12 Months (Previously Unvaccinated):

MenACWY-CRM (Menveo) is the preferred option 1:

  • 2-dose series: First dose at 12 months, second dose at least 12 weeks later (after the first birthday)
  • This provides protection against serogroups A, C, W, and Y

Alternative: MenACWY-D (Menactra) 1:

  • Can be used for infants 9-23 months
  • 2-dose series: Doses separated by at least 12 weeks
  • Important caveat: For children with asplenia or HIV, MenACWY-D should NOT be given before age 2 years due to interference with pneumococcal conjugate vaccine (PCV) response. Must wait until at least 4 weeks after completing all PCV doses 1

If Vaccination Was Started Earlier:

If the infant received MenACWY-CRM starting at 7-11 months 1:

  • Give the second dose at 12 months (at least 12 weeks after the first dose and after the first birthday)

MenB Vaccination Considerations

MenB vaccines are NOT recommended for children under 10 years of age, including 1-year-olds, even those at increased risk 1. MenB vaccination:

  • Is only licensed for ages 10-25 years
  • Has no current indication for infants or toddlers

Booster Dose Requirements for High-Risk Children

For children who remain at increased risk after completing the primary series 1:

  • First booster: 3 years after primary series completion
  • Subsequent boosters: Every 5 years thereafter

Critical Timing Considerations

Interaction with Other Vaccines:

For MenACWY-D (Menactra) 1:

  • Should be given before or at the same time as DTaP to avoid interference with immune response
  • Can be given at any time relative to Tdap or Td

For children with asplenia or HIV 1:

  • Complete all PCV (pneumococcal) doses first
  • Wait at least 4 weeks after final PCV dose before giving MenACWY-D
  • Consider using MenACWY-CRM or MenACWY-TT instead, as these don't have the same PCV interference concerns

Travel Urgency:

If immediate protection is needed for travel 2:

  • The 2 doses can be given as close as 8 weeks apart (rather than the standard 12 weeks)
  • Complete the series before departure if possible

Common Clinical Pitfalls to Avoid

  1. Don't vaccinate healthy 1-year-olds: This is the most common error—meningococcal vaccines are not routine at this age
  2. Don't use MenACWY-D in children with asplenia/HIV before age 2: Use MenACWY-CRM instead to avoid PCV interference
  3. Don't give MenB vaccines to infants: They are not licensed or recommended for children under 10 years
  4. Don't forget the second dose: A single dose is insufficient for the primary series in this age group
  5. Don't confuse with Hib-MenCY-TT (MenHibrix): This combination vaccine is only for infants 2-18 months and only covers serogroups C and Y (not A or W) 2

Documentation and Follow-Up

When vaccinating a high-risk 1-year-old:

  • Document the specific risk factor indication
  • Schedule the second dose at least 12 weeks later
  • Plan for booster doses every 3-5 years depending on age at primary series
  • Educate parents that this protects against serogroups A, C, W, Y but not serogroup B, which causes most infant cases but has no available vaccine for this age group

References

Related Questions

What meningococcal conjugate vaccine (MenACWY) is recommended for a 12‑month‑old infant and what is the appropriate dosing and administration schedule?
Can a 2-year-old child forego the Meningococcal (meningitis) vaccine?
What is the recommended dosing schedule for meningococcal vaccine A (MenA) in children?
Is routine meningococcal vaccination recommended for healthy infants up to 12 months living in Central Europe?
Which FDA‑approved quadrivalent meningococcal conjugate vaccine (Menactra, Menveo, or MenQuadfi) is acceptable as a booster for a healthy 16‑year‑old who received the initial MenACWY dose at age 11‑12?
Is it appropriate to prescribe oxymetazoline nasal spray to a pregnant patient?
What emergency warning signs should prompt a patient discharged after a mild COPD exacerbation to return to the emergency department?
Can an older woman receive O‑positive red blood cell transfusion?
What is the target resting heart rate and recommended medication regimen for patients with an abdominal aortic aneurysm?
Does milnacipran help relieve muscle and joint stiffness, locking, or tightness?
A patient on insulin glargine (Lantus) 20 U daily and prednisone 15 mg in the morning and 10 mg in the evening with a carbohydrate‑to‑insulin ratio of 1 U per 10 g carbs will have the evening prednisone reduced to 5 mg; how should the basal insulin dose and carbohydrate‑to‑insulin ratio be adjusted?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Ask Question